PBGENE-HBV
Chronic Hepatitis B Virus (HBV) Infection
Phase 1/2Active (ELIMINATE-B Trial)
Key Facts
Indication
Chronic Hepatitis B Virus (HBV) Infection
Phase
Phase 1/2
Status
Active (ELIMINATE-B Trial)
Company
About Precision BioSciences
Precision BioSciences is a clinical-stage biotech leveraging its proprietary ARCUS genome editing platform to develop potentially curative in vivo therapies for genetic diseases. The company has advanced two wholly-owned programs into Phase 1/2 trials: PBGENE-HBV for chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy, both supported by key regulatory designations. Its strategy combines advancing these core assets with strategic partnerships to validate and fund the ARCUS platform, positioning it in the competitive but high-potential gene editing landscape.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Virus (HBV) Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| Lead Gene Therapy Program | HBVtech | Pre-clinical |
| IMC-M113V (HBV ImmTAV) | Immunocore | Phase 1 |